The protective action of radix Astragalus membranaceus against hapten-induced colitis through modulation of cytokines

Cytokine

Volumn 47, Issue 2, 2009, Pages 85-90

  Ko, Joshua Ka Shun ^a   Chik, Cecilia Wai Shan ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

Astragalus membranaceus; Colitis; Cytokines; Immunomodulation

Indexed keywords

ASTRAGALUS MEMBRANACEUS EXTRACT; GAMMA INTERFERON; HAPTEN; INTERLEUKIN 10; INTERLEUKIN 1BETA; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; DRUG MEGADOSE; IMMUNOREGULATION; MALE; NONHUMAN; PLANT ROOT; PRIORITY JOURNAL; RAT;

ANIMALS; ASTRAGALUS MEMBRANACEUS; COLITIS; COLON; CYTOKINES; DINITROFLUOROBENZENE; HAPTENS; MALE; PHYTOTHERAPY; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY;

ASTRAGALUS MEMBRANACEUS; RATTUS;

EID: 67650632775     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.05.014     Document Type: Article

References (31)

1. Hanauer S.B. Drug therapy: inflammatory bowel disease. N Engl J Med 334 (1996) 841-848
2. Sartor R.B. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 92 (1997) S5-S11
3. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115 (1998) 182-205
4. Farrell R.J., and Peppercorn M.A. Ulcerative colitis. Lancet 359 (2002) 331-340
5. Dinarello C.A. Proinflammatory cytokines. Chest 118 (2000) 503-508
6. Opal S.M., and DePalo V.A. Anti-inflammatory cytokines. Chest 117 (2000) 1162-1172
7. Ma X.Q., Shi Q., and Duan J.A. Chemical analysis of Radix astragali (Huangqi) in China: a comparison with its adulterants and seasonal variations. J Agric Food Chem 50 (2002) 4861-4866
8. McKenna D.J., Hughes K., and Jones K. Astragalus. Int J Integr Med 4 (2002) 40-46
9. He Z.-Q., and Findlay J.A. Constituents of Astragalus membranaceus. J Nat Prod 54 (1991) 810-815
10. Lin L.Z., He X.G., and Lindenmaier M. Liquid chromatography-electrospray ionization mass spectrometry study of the flavoniods of the roots of Astrgalus mongholicus and A. Membranaceus. J Chromatogr A 876 (2000) 87-95
11. Bedir E., Pugh B., Calis I., Pasco D.S., and Khan I.A. Immunostimulatory effects of cycloartane-type triterpene glycosides from Astragalus species. Biol Pharm Bull 23 (2000) 834-837
12. Jiao Y., Wen J., and Yu X. Influence of flavonoid of Astragalus membranaceus's stem and leave on the function of cell mediated immunity in mice. Zhongguo Zhong Xi Yi Jie He Za Zhi 19 (1999) 356-358
13. Yu Y.Q., and Sun W.Z. Study on regulation effects of TNF-α, IL-8 and sIL-2r content to patients of ulcerative colitis by mediation method. J Harbin Univ Commun Nat Sci 18 (2002) 248-250
14. Hawkins J.V., Emmel E.L., Feuer J.J., Nedelman M.A., Harvey C.J., Klein H.J., Rozmiarek H., Kennedy A.R., Lichtenstein G.R., and Billings P.C. Protease activity in a hapten-induced model of ulcerative colitis in rats. Digest Dis Sci 42 (1997) 1969-1980
15. Cho C.H., and Ko J.K.S. Herbal medicines and animal models of gastrointestinal diseases. In: Gad S. (Ed). Drug Discovery handbook (2005), John Wiley & Sons, Hoboken 1013-1035 [chapter 22]
16. Pharmacopoeia Commission of the People's Republic of China. Pharmacopoeia of the People's Republic of China. vol. I (English ed.). Beijing: Chemical Industry Press; 2000. p. 161-2.
17. Wallace J.L., and Keenan C.M. An orally active inhibitor of leukotriene synthesis accelerated healing in a rat model of colitis. Am J Physiol 258 (1990) G527-G534
18. Ko J.K.S., Sham N.F., Guo X., and Cho C.H. Beneficial intervention of experimental colitis by passive cigarette smoking through the modulation of cytokines in rats. J Invest Med 49 (2001) 21-29
19. Ko J.K.S., Lam F.Y.L., and Cheung A.P.L. Amelioration of experimental colitis by Astragalus membranaceus through anti-oxidation and inhibition of adhesion molecule synthesis. World J Gastroenterol 11 (2005) 5787-5794
20. Brandtzaeg P., Haraldsen G., and Helgeland L. New insights into the immunopathology of human inflammatory bowel disease. Drugs Today 35 (1999) S33-S70
21. Lakatos L. Immunology of inflammatory bowel diseases. Acta Physiol Hung 87 (2000) 355-372
22. MacDonald T.T., Monteleone G., and Pender S.L.F. Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol 51 (2000) 2-9
23. Ko J.K.S., and Cho C.H. The diverse actions of nicotine and different extracted fractions from tobacco smoke against hapten-induced colitis in rats. Toxicol Sci 87 (2005) 285-295
24. Sartor R.B. Cytokines in intestinal inflammation: pathophysiology and clinical considerations. Gastroenterology 106 (1994) 533-539
25. Ardizzone S., and Porro G.B. Inflammatory bowel disease: new insights into pathogenesis and treatment. J Int Med 252 (2002) 475-496
26. Bedir E., Pugh B., Calis I., Pasco D.S., and Khan I.A. Immunostimulatory effects of cycloartane-type triterpene glycosides from Astragalus species. Biol Pharm Bull 23 (2000) 834-837
27. Schreiber S., Heinig T., Thiele H.G., and Raedler A. Immunoregulatory role of interleukin-10 in patients with inflammatory bowel disease. Gastroenterology 108 (1995) 1434-1444
28. Shao B.M., Xu W., Dai H., Tu P., Li Z., and Gao X.M. A study on the immune receptors for polysaccharides from the roots of Astragalus membranaceus, a Chinese medicinal herb. Biochem Biophys Res Commun 320 (2004) 1103-1111
29. Wang Y., Qian X.J., Hadley H.R., and Lau B.H. Phytochemicals potentiate interleukin-2 generated lymphokine-activated killer cell cytotoxicity against murine renal cell carcinoma. Mol Biother 4 (1992) 143-146
30. Wang Y.P., Li X.Y., Song C.Q., and Hu Z.B. Effect of astrgaloside IV on T, B lymphocyte proliferation and peritoneal macrophage function in mice. Acta Pharmacol Sin 23 (2002) 263-266
31. Zhang W.-J., Hufnagl P., Binder B.R., and Wojta J. Antiinflammatory activity of astragaloside IV is mediated by inhibition of NF-κB activation and adhesion molecule expression. Thromb Haemost 90 (2003) 904-914